Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
PYC Therapeutics Limited ( (AU:PYC) ) has shared an update.
PYC Therapeutics Limited has announced a trading halt on its securities pending an announcement regarding a proposed capital raising. This decision is expected to impact the company’s market activity, with the trading halt lifted by February 19, 2025, following the release of the announcement. The move indicates strategic financial planning aimed at furthering the company’s development efforts in its target therapeutic areas.
More about PYC Therapeutics Limited
PYC Therapeutics (ASX: PYC) is a biotechnology company focused on developing innovative RNA therapies. The company combines its drug design capabilities with a proprietary drug delivery platform to create a pipeline of therapies targeting inherited eye diseases, neurodevelopmental, and kidney diseases. PYC’s operations span discovery, pre-clinical, and laboratory work in Australia, with clinical translation globally.
YTD Price Performance: -2.65%
Average Trading Volume: 405,310
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$599.6M
For an in-depth examination of PYC stock, go to TipRanks’ Stock Analysis page.
